Longeveron(LGVN) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Longeveron Announces Second Quarter 2024 Financial Results and Provides Business Update ● Positive data from the Phase 2a clinical trial (CLEAR MIND ) evaluating Lomecel-B in Alzheimer's disease presented in Featured Research Oral Presentation at Alzheimer's Association International Conference® (AAIC) ● U.S. FDA granted Lomecel-B™ both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer's disease ● Phase 2b clinical trial (EL ...